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Executive Summary
Executive Summary
Heart disease is the leading cause of death in men and women in the United States. Together, heart disease, stroke, 
and other vascular diseases claim over 800,000 lives each year.1,2 An estimated one in every seven US dollars spent 
on health care goes toward cardiovascular disease (CVD), totaling over $300 billion in annual health care costs and 
lost productivity from premature death each year.3,4 Several modifiable risk factors for CVD are well known, including 
hypertension, hyperlipidemia, smoking, being overweight, being inactive, and eating an unhealthy diet. Although 
treatments for hypertension and hyperlipidemia are very effective and relatively inexpensive, most people with these 
conditions do not have them under control.
Although individuals can take steps to reduce their own risks of CVD, public health approaches have the potential to 
reduce risks among entire populations. Changes to policies, practices, and health systems that are designed to lower 
uncontrolled high blood pressure and cholesterol levels among populations can significantly improve access to health 
care, quality of care, and patient adherence to treatments.
The Centers for Disease Control and Prevention’s Division for Heart Disease and Stroke Prevention (DHDSP) is guided 
by its mission to provide public health leadership to improve cardiovascular health for all, reduce the burden of CVD, 
and eliminate disparities associated with heart disease and stroke. 
DHDSP supports all 50 states and the District of Columbia to work 
toward achieving this mission, which aligns with the National Center 
for Chronic Disease Prevention and Health Promotion’s (NCCDPHP’s) 
approach to preventing chronic disease through four key domains5,6:
• Domain 1: Epidemiology and Surveillance.
• Domain 2: Environmental Approaches.
• Domain 3: Health Care System Interventions.
• Domain 4: Community Programs Linked to Clinical Services.
Because resources are limited and the need to prevent CVD is 
widespread, decision makers and public health professionals must 
choose strategies that are effective and sustainable. The four domains 
provide a framework for these efforts, and scientific evidence can help guide decisions about which strategies to 
adopt. In this publication, Best Practices for Cardiovascular Disease Prevention Programs: A Guide to Effective Health 
Care System Interventions and Community Programs Linked to Clinical Services (hereafter called the Best Practices Guide 
for CVD Prevention), we describe and summarize scientific evidence behind effective strategies for lowering high 
blood pressure and cholesterol levels that can be implemented in health care systems (Domain 3) and that involve 
community programs linked to clinical services (Domain 4). Following the best practices framework put forth by a 
CDC work group7 and using a translation tool called the Continuum of Evidence of Effectiveness,8,9 we have reviewed, 
identified, and summarized the evidence behind strategies that can be considered best practices for controlling 
hypertension and hyperlipidemia.
The target audience for this publication includes state and local health departments, decision makers, public health 
professionals, and other stakeholders interested in using proven strategies to improve cardiovascular health. This 
publication is not intended as comprehensive guidance, but rather a high-level, supportive resource. Our intention is 
to present brief, easy-to-follow evidence summaries for effective blood pressure and cholesterol control strategies and 
to highlight available resources and tools useful for implementing these strategies. 
Because resources are limited 
and the need to prevent CVD is 
widespread, decision makers and 
public health professionals must 
choose strategies that are effective 
and sustainable. 
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Highlighted strategies include the following:
• Using a team-based care model.
• Elevating pharmacy involvement in patient care.
• Including community health workers on clinical care teams.
• Activating patient involvement through self-management.
• Using clinical decision support systems.
• Reducing out-of-pocket costs for medications.
These strategies were identified through the recommendations of end users, grantees, evaluators, content subject 
matter experts, and program specialists, and they are based on the priorities of DHDSP. Each of the selected strategies 
was vetted by a DHDSP work group, and evidence was reviewed by people with expertise in research methods, 
program delivery, and the proposed strategies. To be included in the Best Practices Guide for CVD Prevention, strategies 
had to be supported by multiple high-quality research studies that demonstrated evidence of effectiveness in 
controlling blood pressure or cholesterol levels. In this publication, we describe the strength of evidence behind each 
strategy and the reported outcomes related to CVD prevention. We also highlight the public health and economic 
impacts of each strategy, including whether it improves health or reduces health disparities.
In addition, we highlight important issues related to the implementation of each strategy, including settings in which 
the strategies have been implemented, resources available to support implementation, and policy and law-related 
considerations. Brief synopses, called Stories from the Field, highlight specific locations where the strategies have 
been successfully implemented. 
This publication also provides several appendices with additional information. Appendix A provides a summary of 
the evidence of effectiveness for each strategy. Appendix B explains the Rapid Synthesis and Translation Process, 
which was one of the methods used to develop this publication. Appendix C provides details about the Continuum of 
Evidence of Effectiveness, which is an interactive, online tool that was used to assess and rate the strength of evidence 
for each strategy. Appendix D is a glossary of important terms used in this publication. 
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Introduction
Public health strategies to detect, prevent, and control chronic disease can 
be implemented at many levels, from individual behavioral interventions 
to environmental or cultural strategies affecting entire communities. 
Making changes to health system practices can eliminate barriers to quality 
care and improve the health of many people. Nowhere is the need for such 
approaches more apparent than in the efforts to prevent heart disease, the 
leading cause of death in men and women in the United States. Although 
treatments for hypertension and hyperlipidemia—two key risk factors for 
cardiovascular disease (CVD)—are very effective and relatively inexpensive, 
most people with these conditions do not have them under control. 
Research on strategies to lower blood pressure and cholesterol levels in 
health care settings offers insights about effective practices, but more work 
is needed to translate this evidence into action.
This publication, Best Practices for Cardiovascular Disease Prevention 
Programs: A Guide to Effective Health Care System Interventions and Community Programs Linked to Clinical Services 
(hereafter called the Best Practices Guide for CVD Prevention), is intended as a translation resource. It highlights 
strategies that have been found to be effective for widespread control of hypertension and hyperlipidemia, but which 
are not yet being used widely as standard practice.
Together, heart disease, stroke, and other vascular diseases claim over 800,000 lives in the United States each year and 
cost over $300 billion in annual health care costs and lost productivity from premature death.1–3 An estimated one 
in every seven US dollars spent on health care goes toward CVD.3,4 This costly and deadly disease is at the forefront 
of public health priorities at the Centers for Disease Control and Prevention (CDC), and health care practitioners at 
many levels are looking for solutions. Several modifiable risk factors for CVD are well known, including hypertension, 
hyperlipidemia, smoking, being overweight, being inactive, and eating an unhealthy diet.
Identifying effective ways to directly lower high blood pressure and cholesterol in the US population is a priority for 
the Centers for Disease Control and Prevention’s (CDC’s) Division for Heart Disease and Stroke Prevention (DHDSP). 
Other divisions in CDC’s National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP) prioritize 
other risk factors, such as smoking, diabetes, diet, and obesity. DHDSP supports all 50 states and the District of 
Columbia to work toward achieving DHDSP’s mission to improve cardiovascular health for all, reduce the burden of 
CVD, and eliminate disparities associated with heart disease and stroke.
[The Best Practices Guide for 
CVD Prevention] highlights 
strategies that have been found 
to be effective for widespread 
control of hypertension and 
hyperlipidemia, but which are 
not yet being used widely as 
standard practice.
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Background
Key Domains of Chronic Disease Prevention and Health Promotion
NCCDPHP takes a multifaceted approach to chronic disease detection, prevention, and control by focusing on four 
key domains: epidemiology and surveillance (Domain 1), environmental approaches (Domain 2), health care system 
interventions (Domain 3), and community programs linked to clinical services (Domain 4).5
Domain 1: Epidemiology and Surveillance
Epidemiology and surveillance involves the use of systems to regularly track and monitor current and emerging trends 
in chronic diseases and their related risk factors.  Investing in this domain allows data to be collected to understand 
the incidence, prevalence, and risk factors of chronic diseases; identify effective approaches for detection, prevention, 
and control; and monitor and assess progress toward key program goals.5,6 Surveillance is essential for monitoring 
the detection, prevention, control, and treatment of CVD. CDC uses data from communities, health systems, and 
administrative systems to assess the burden of CVD. CDC tracks trends in cardiovascular risk factors and disease and 
shares findings with partners and collaborators working to apply public health strategies to improve cardiovascular 
health. Grantees of CDC-funded heart disease and stroke prevention programs collect surveillance data and use this 
information to guide, prioritize, and monitor program delivery.
Domain 2: Environmental Approaches
Environmental approaches involve the use of policy and structural changes to create environments where health is 
promoted and healthy choices are reinforced. Changes can be made to social and physical environments that make 
healthy behaviors easier and more convenient for individuals, while maintaining broad reach and sustaining health 
benefits for overall populations.5,6 CDC and its partners are working to make healthier environments a reality for those 
at greatest risk for CVD. Environmental strategies that can help reduce heart attacks and strokes include creating 
smoke-free environments and increasing access to healthier foods, including those with less sodium.
Domain 3: Health Care System Interventions
Health care system interventions are strategies used to improve the delivery and quality of care in clinical settings. 
Health system and quality improvement changes, such as using electronic health records (EHRs) and requiring 
reporting on blood pressure control, can encourage health care providers to better monitor and address key risk 
factors for CVD.5,6 Such strategies can result in earlier detection, improved disease management, and even prevention 
of the onset of CVD.
Domain 4: Community Programs Linked to Clinical Services
This domain—sometimes called community-clinical links—refers to strategies that connect community programs 
with health systems to improve chronic disease prevention, care, and management.5 Because this strategy relies on 
links between community and clinical settings, activities often overlap Domains 3 and 4. Community-clinical links 
aim to ensure that people with or at high risk for chronic diseases have access to quality community resources and 
support to prevent, delay, or manage chronic conditions once they occur. Strategies can include referrals by clinicians 
to community supports to improve chronic disease self-management or referrals by community programs to clinical 
services.5,6 These links can also involve community delivery and third-party payment for effective programs, which can 
reduce barriers and increase adherence to clinician recommendations. 
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Focus of the Best Practices Guide 
for CVD Prevention
The Best Practices Guide for CVD Prevention focuses specifically on strategies used in Domains 3 and 4, health care 
systems interventions (Domain 3) and community programs linked to clinical services (Domain 4). Improvements 
made in these areas can help create environments where people are better able to receive quality care, make healthier 
choices, and take control of their health. CDC funds state and local programs and key partner organizations to put 
health care system interventions and community-clinical links into action to prevent CVD. See Appendix A for a 
summary of effective strategies within these domains.
Health Care System 
Interventions (Domain 3)
Examples of health care system interventions include 
efforts to increase identification of undiagnosed 
hypertension, adopt clinical hypertension protocols, 
improve medication adherence, increase the use of 
health information technology to implement the 
ABCS (Aspirin when appropriate, Blood pressure 
control, Cholesterol management, and Smoking 
cessation), and make other quality improvements in 
health care practices.
Community Programs Linked 
to Clinical Services (Domain 4)
Examples of activities involving community-clinical 
links include health care systems collaborating with 
community groups that provide evidence-based 
lifestyle programs; using community health care 
extenders (i.e., non-MD health care professionals) to 
support self-managed blood pressure; and collaborating 
with chronic disease programs for effective program 
planning, implementation, and evaluation.
Intended Audience
The Best Practices Guide for CVD Prevention was developed for state and local health departments, decision makers, 
public health professionals, and other stakeholders with an interest in implementing effective strategies to improve 
cardiovascular health. To develop this publication, we searched for interventions and strategies that have been 
found to be effective for CVD prevention in multiple research and practice settings, but which are not yet widely 
used or considered standard practice. For each selected strategy, we provide brief summaries of the research 
evidence and links to information and resources on how to implement the strategy. The information presented here 
is not comprehensive, but instead provides a quick reference to selected strategies. The Best Practices Guide for CVD 
Prevention can be used as a resource by decision makers and stakeholders who wish to implement CVD prevention 
strategies that offer the best chances for successful outcomes in their communities and health care systems. In 
addition to the strategy summaries, this publication provides several appendices with additional information, 
including a glossary of important terms (Appendix D). 
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Guide Development
The strategies presented in this publication were identified and confirmed through an extensive review process, with 
input from subject matter experts (SMEs) and practice partners both within and external to CDC. Internally, strategies 
were reviewed and vetted by DHDSP senior leadership and staff in DHDSP’s Program Development and Services 
Branch, Epidemiology and Surveillance Branch, Applied Research and Evaluation Branch, Million Hearts® team, and 
Office of Policy, External Relations, and Communications. Externally, we worked with academics, partners, and program 
directors with expertise in chronic care delivery, CVD prevention and control, and public health program management.
In addition to the review process, the Best Practices Guide for CVD Prevention was conceptualized and developed using 
several theoretical models. The concept of identifying public health best practices for hypertension and cholesterol 
control was primarily guided by the best practices framework developed by a CDC work group.7 This framework also 
guided how we selected strategies, reported their impact, and offered considerations for implementation.
Best Practices Framework
According to the best practices framework 
(Figure 1), strategies considered best practices 
should be evidence-based; have high-quality 
evidence to support them; and demonstrate a 
positive impact in terms of effectiveness, reach, 
feasibility, sustainability, and transferability.7 
Where a particular practice falls on the best 
practices continuum at any point in time is 
dependent on the evidence available at that 
point. Thus, being labeled a “best practice” is not 
a static designation, but one that can change as 
new evidence becomes available. Practices can be 
categorized as emerging, promising, leading,  
or best.
Other Guiding Frameworks
In addition to using the best practices framework 
to develop this publication, we also followed a 
process adapted from the Rapid Synthesis and 
Translation Process (RSTP).8 For more information 
on RSTP, see Appendix B. RSTP provides a structure 
for working with SMEs and practice partners to 
develop an evidence-based translation product. 
In addition, for each strategy, two evidence 
reviewers used an interactive, online tool called 
the Continuum of Evidence of Effectiveness to 
assess and rate the strength of evidence for each 
proposed best practice.9 For more information 
about this tool, see Appendix C. 
Figure 1. A Conceptual Framework for Planning and 
Improving Evidence-Based Practices
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Interpreting the Results: Best Practice Strategy Template
We used the information collected and assessed through the review process to identify effective strategies, or best 
practices, for controlling blood pressure or cholesterol levels. We then summarized the evidence to support each of 
these strategies into a standard template. The sample template presented on the following pages describes what 
information is provided for each strategy and how this information is organized.
This box provides a 
short summary of 
the findings for the 
strategy.
An example of where 
the strategy has 
been implemented is 
provided here.
A brief description 
of the strategy starts 
each section.
Here we provide 
summary ratings 
indicating the 
strength of research 
evidence behind 
the strategy.
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The Continuum 
of Evidence of 
Effectiveness is 
designed to assess 
the quality of the 
research evidence 
available, but it 
cannot directly 
assess a strategy’s 
potential for public 
health impact, which 
is an important 
component of 
a best practices 
designation. 
To assess this 
component, 
reviewers examined 
the research 
literature for 
evidence of a 
strategy’s potential 
to improve health, 
reduce health 
disparities, and 
show economic 
sustainability. They 
assigned ratings 
for each of these 
categories. These 
ratings are provided 
in a table like the 
example shown here.
The reviewers used the Continuum of Evidence of Effectiveness to assess the 
effectiveness of each strategy according to six dimensions. The interactive 
continuum tool summarized their ratings for each dimension and we have 
summarized those results in a table like the example shown here. See Appendix 
A for a summary of the ratings for all strategies.
The Health Disparity 
Impact section 
describes the 
evidence from the 
research literature 
and provides a 
rationale for the 
rating for health 
disparity impact. 
The rating indicates 
whether the strategy 
is effective among the 
populations with the 
most need or has the 
potential to reduce 
health disparities.
The Health Impact 
section describes the 
evidence from the 
research literature and 
provides a rationale 
for the rating for 
health impact. The 
rating indicates 
whether the strategy 
achieves one or more 
desired outcomes 
related to CVD 
prevention—such 
as lowered blood 
pressure, increased 
adherence to blood 
pressure medication, 
or decreased disease 
and death.
The Economic Impact section describes the evidence available on a variety of economic factors, 
including overall cost-effectiveness; cost savings to health systems, patients, or other payers; 
net benefit; and return on investment (ROI). The economic impact rating reflects the degree to 
which evidence exists that the strategy can have a positive economic impact. Cost figures shown 
in this section are examples of possible impact according to the best available evidence. All costs 
are adjusted to 2015 US dollars using the price index for personal consumption expenditures 
prepared by the Bureau of Economic Analysis in the US Department of Commerce.10
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This section describes the strategy as it is being applied in a specific community, clinical, or 
health care setting. It provides contact information, results and clinical outcomes, and an 
assessment of factors that affect implementation and sustainability. This information can be 
useful to state and local health departments, decision makers, public health professionals, and 
related stakeholders.
This section provides information about the 
implementation of each strategy, including 
settings, implementation guidance, resources, 
and policy and law-related considerations.
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Current, high-level 
considerations 
related to policy 
and laws relevant 
to implementing 
the strategy.
Available 
resources, such as 
guides, examples, 
and guidelines 
that support 
implementation of 
the strategy. 
Settings in which 
the strategy 
was successfully 
implemented.
Current 
implementation 
guidance available 
to assist with 
implementation of 
the strategy.
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Limitations of This Guide
Although the Best Practices Guide for CVD Prevention is a useful resource on evidence-based strategies for preventing 
CVD, it has several limitations. First, it does not include every strategy found to be effective in CVD prevention. Other 
strategies may be used in practice that are not included here because of the approach we used to select and assess 
the evidence. This guide focuses on practices that are best characterized in the research literature and therefore most 
amenable to meaningful assessment by the methods we used. Second, this publication provides only a condensed 
version of the evidence available on each strategy. It is not a systematic review, like The Guide to Community Preventive 
Services, and thus could be missing potentially relevant information about strategy weaknesses and research 
limitations. References to longer and more detailed systematic reviews and meta-analyses are provided when available.
Third, our presentation of evidence is limited by the available literature. Consequently, if key data (for example, on 
economic factors) were not available at the time we reviewed the evidence, this information is missing. Fourth, 
information on the economic impact of the strategies is presented using a variety of methods, which limits the ability 
to make direct comparisons across practices. The numbers presented should be read only as examples of the best 
available evidence demonstrating positive economic impact. They should not be directly compared to examine the 
comparative efficiency of the different practices. Fifth, this initial version of the Best Practices Guide for CVD Prevention 
does not provide detailed information on strategy implementation or the estimated costs of implementation. 
Although we have provided links to available implementation resources when possible, providing complete 
implementation guidance for each strategy was beyond the scope of this publication. Such information may be 
included, to the extent possible, in future versions.
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Health Care System 
Interventions 
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Domain 3: Health Care System Interventions
Health care system interventions have the potential to improve 
the delivery and quality of care in clinical settings. Effective strategies in this domain can lead 
to earlier detection, improved disease management, and even prevention of the onset of CVD.
Promoting Team-
Based Care to Improve 
Hypertension Control
Pharmacy: Collaborative 
Practice Agreements to 
Enable Collaborative Drug 
Therapy Management
Self-Measured Blood 
Pressure Monitoring with 
Clinical Support
Self-Management Support 
and Education
Reducing Out-of-Pocket 
Costs for Medications
Implementing Clinical 
Decision Support Systems
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Evidence of Impact
Health 
Impact
Health 
Disparity 
Impact
Economic 
Impact
Legend: Supported Moderate Insufficient
Evidence of Effectiveness
Effect Implementation Guidance
Research 
Design
Internal 
Validity
Independent
Replication
External & 
Ecological 
Validity
Legend: Well supported/
Supported
Promising/
Emerging
Unsupported/
Harmful
Promoting Team-Based Care to Improve 
High Blood Pressure Control
Team-based care is a strategy that can be implemented at the health system level to 
enhance patient care by having two or more health care providers working collaboratively 
with each patient. Within the context of cardiovascular disease (CVD) prevention, it often 
involves a multidisciplinary team working in collaboration to educate patients, identify 
risk factors for disease, prescribe and modify treatments, and maintain an ongoing dialog 
with patients about their health and care.1,2 These teams may include doctors, nurses, 
pharmacists, community paramedics, primary care providers, community health workers, 
and others (e.g., dietitians).
Summary
Team-based care, involving 
collaboration between 
doctors, nurses, pharmacists, 
paramedics, and others, is a cost-
effective strategy for increasing 
medication adherence and 
lowering blood pressure among 
diverse populations and in 
various settings.
Stories From the Field:  
WinMed Health Services 
(Cincinnati, Ohio).
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Evidence of Effectiveness
The evidence base for implementing team-based care in health care systems and practices is very strong. Solid evidence exists 
that this strategy achieves desired outcomes, with studies demonstrating internal and external validity. This strategy has also been 
independently replicated, which shows reliability of impact. Several randomized controlled trials, which are often considered the 
gold standard in research, have been conducted and show positive results from using multidisciplinary teams as a way to improve 
hypertension control. Various organizations, such as the American Medical Association and the Agency for Healthcare Research 
and Quality (AHRQ), have developed guidelines to help health care systems and practices implement this strategy as part of their 
policies and protocols.
Evidence of Impact
Health Impact
A systematic review by the Community 
Preventive Services Task Force 
concluded that team-based care 
can lead to significantly improved 
hypertension control, lowered systolic 
and diastolic blood pressure levels 
(overall median reductions were 5.4 
mmHg and 1.8 mmHg, respectively), 
and improved patient adherence to 
hypertensive medication.3
Health Disparity Impact
Team-based care has been found to 
be effective when used among diverse 
patient populations, including those 
with members of different racial and 
ethnic groups (e.g., whites, African 
Americans) and among patients with 
multiple health conditions.
Evidence also exists that this strategy 
is effective among low-income 
populations. Additional research is 
needed to examine effectiveness among 
populations that are primarily Hispanic 
and in communities with other minority 
populations.3
Economic Impact
Team-based care has proven to be 
cost-effective. The median total cost 
for providing team-based care for 
hypertension control was found to be 
$355 per person per year. The median 
cost per quality-adjusted life year 
(QALY) gained over 20 years was either 
$10,511 or $15,137, depending on 
the QALY conversion method used.4 
Both estimates were well below the 
commonly used and conservative 
cost-effectiveness threshold of $50,000 
per QALY.
Researchers modeled the health 
and economic impact of nationwide 
adoption of team-based care for 
hypertension over 10 years and 
estimated a net cost savings to 
Medicare of $5.8 billion (2012 US 
dollars) over this period.5 This model 
also estimates an overall national 
savings of $25.3 billion in averted 
disease costs, which offsets an 
estimated $22.9 billion cost of using 
this intervention to the health care 
system. Costs for patient time over this 
period are estimated at $15.8 billion, 
but are largely offset by an estimated 
$11 billion in productivity gains.
The evidence base for 
implementing team-based care in 
health care systems and practices 
is very strong.
Stories from the Field
Team-Based Care
Team-Based Care at WinMed Health Services
WinMed Health Services, an FQHC in Cincinnati, Ohio, is a 2014 Million Hearts® Hypertension 
Control Champion that successfully incorporated team-based care to help achieve 
hypertension control among its patients. To ensure a continuum of complete patient 
care, WinMed’s care teams include physicians, pharmacists, and behavioral and dental 
professionals. WinMed focuses on increasing health care providers’ expertise and skills, 
providing opportunities for patient education, ensuring that patient care is team-based, 
and using registry-based information systems. The WinMed care teams use electronic health 
records to increase proper communication between patients and the different providers. By 
improving community ties and patient education, encouraging greater patient engagement, 
and adding pharmacists and patient assisters to the health care team, WinMed achieved a 
7% increase in hypertension control among its patients from 2013 to 2014.
For more information:
Website: www.winmedinc.org/index.htm
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Four Considerations for Implementation
1 Settings
Team-based care has been successfully implemented in multiple settings, including Federally Qualified 
Health Centers (FQHCs), patient-centered medical homes, and managed health care systems, in various 
locations throughout the United States.
2 Policy and Law-Related Considerations
Scope-of-practice laws and organizational policies that allow nurses, physician assistants, pharmacists, and 
other health care providers to practice to the full extent of their licensure and training can facilitate team-
based care.
3 Implementation Guidance
The American Medical Association and AHRQ have developed modules for implementing team-based care:
• American Medical Association’s STEPSforward: Implementing Team-Based Care.6
• Agency for Healthcare Research and Quality’s Practice Facilitation Handbook.7
4 Resources
Many federal initiatives and medical institutions support team-based care approaches. Examples include 
the following:
• Centers for Disease Control and Prevention’s 6|18 Initiative.8
• National High Blood Pressure Educational Program, supported by the National Heart, Lung, and 
Blood Institute.2
• American Heart Association.9
• National Academy of Medicine.10
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Pharmacy: Collaborative Practice 
Agreements to Enable Collaborative 
Drug Therapy Management
Collaborative drug therapy management (CDTM), also known as coordinated drug therapy 
management, involves developing a collaborative practice agreement (CPA) between one 
or more health care providers and pharmacists. A CPA allows qualified pharmacists working 
within the context of a defined protocol to assume professional responsibility for performing 
patient assessments, counseling, and referrals; ordering laboratory tests; administering 
drugs; and selecting, initiating, monitoring, continuing, and adjusting drug regimens.1 The 
use of CDTM through a CPA is a strategy that can be considered to straddle both Domains 3 
(health care system interventions) and 4 (community-clinical links).
Evidence of Impact
Health 
Impact
Health 
Disparity 
Impact
Economic 
Impact
Legend: Supported Moderate Insufficient
Summary
CDTM enabled by a CPA is a 
formal partnership between 
qualified pharmacists and 
prescribers to expand a 
pharmacist’s scope of practice. 
CDTM is a cost-effective 
strategy for lowering blood 
pressure, blood sugar, and LDL 
cholesterol levels; improving 
treatment quality; and increasing 
medication adherence.
Stories From the Field:  
El Rio Community Center (Pima 
County, Arizona).
Evidence of Effectiveness
Effect Implementation Guidance
Research 
Design
Internal 
Validity
Independent
Replication
External & 
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Validity
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Evidence of Effectiveness
Strong evidence exists that CDTM enabled by a CPA is effective. Solid evidence exists that this strategy achieves desired outcomes, 
with studies demonstrating internal and external validity. This strategy has also been independently replicated, and systematic 
reviews assessing the use of CDTM have confirmed reliability of impact. Implementation guidance on CPAs to enable CDTM was 
found to be lacking in comprehensiveness.
Evidence of Impact
Health Impact
CDTM, enabled by CPAs between 
pharmacists and other health care 
providers, has been shown effective in 
improving clinical and behavioral health 
indicators, including lowering blood 
pressure, HbA1c, and LDL cholesterol 
levels; improving treatment quality 
through pharmacist compliance with 
clinical guidelines; and increasing 
patient knowledge and adherence to 
medication regimens.2
Health Disparity Impact
The goals of reaching populations at 
risk and reducing health disparities 
have been taken into account in the 
development and implementation 
of CPAs, particularly by pharmacy 
organizations (e.g., the American 
Pharmacists Association), state medical 
and pharmacy boards, and state 
pharmacy organizations. However, no 
studies have directly examined the 
impact of CPAs between pharmacists 
and providers serving low-income 
populations. Because pharmacists 
often work directly with the public in 
community settings, they are often 
considered the public’s most accessible 
health care providers. CPAs can 
authorize pharmacists to make changes 
to a patient’s medication or dosage, 
which can reduce the number of visits 
a patient has to make and lower costs, 
while also making it easier for patients 
to adhere to their medications.
Economic Impact
Research suggests that clinical 
pharmacy services like CDTM can 
be cost-saving to the health care 
system, primarily through avoided 
hospitalizations and emergency room 
(ER) visits.3 For example, in 2006, 
Missouri’s Pharmacy-Assisted CDTM 
program resulted in a 12% decrease 
in any-cause hospitalizations, a 25% 
reduction in ER visits, and a decrease 
in drug-related problems among 
beneficiaries after 1 year. This program 
was also found to have a 2.5 to 1 ROI to 
the state, with an estimated savings of 
$518.10 per patient per month.3 
Strong evidence exists that CDTM 
enabled by a CPA is effective.
Stories from the Field
Collaborative Practice Agreements
CPAs at El Rio Community Center
El Rio Community Health Center serves over 75,000 people in 
Pima County, Arizona. In 2011, 20% of El Rio’s adult patients (8,954 
of 44,952) had diagnosed hypertension, but only 67% of those 
diagnosed had the condition under control. Pharmacists at El 
Rio were encouraged to establish CPAs with the center’s medical 
providers. These agreements enable pharmacists to work directly 
with patients to help them manage their hypertension and other 
chronic conditions, such as diabetes and hyperlipidemia. Within 
the scope of the CPA, pharmacists have the discretion to change 
patient medications. After CDTM was implemented, El Rio reported 
improved clinical outcomes (e.g., lower cholesterol and blood 
pressure levels), increased use of recommended screenings, and 
reduced ER visits. The El Rio case study highlights several important 
considerations for CDTM implementation. These considerations 
include instilling mission-driven values through training and 
orientation, accepting pharmacy student interns, and using broad 
strategies and networks to improve patient care and increase 
potential partnerships that may extend the use of CPAs.
For more information:
Phone: 520-670-3909
Website: www.elrio.org
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Four Considerations for Implementation
1 Settings
Enabling CDTM through CPAs has been found to be effective in several clinical and community settings, 
including federally qualified health centers (FQHC), patient-centered medical homes, managed care health 
systems, community pharmacies, hospital pharmacies, and primary care clinics.
2 Policy and Law-Related Considerations
CPAs are typically authorized through state scope-of-practice laws that may or may not allow for their 
use within pharmacist scope-of-practice laws. Challenges associated with billing for services exist, even 
at the federal level.12,13 When a CPA is developed, the pharmacist and the prescriber work together to 
develop the terms of the CPA. They may use recommendations and model language available from various 
organizations.5,6,14
3 Implementation Guidance
CDC has recently developed a CPA tool kit that provides implementation guidance:
• Advancing Team-Based Care Through Collaborative Practice Agreements: A Resource and 
Implementation Guide for Adding Pharmacists to the Care Team.4
Guidance from the state level comes from the following sources:
• National Association of State Pharmacy Associations.5
• American Pharmacy Association.6
4 Resources
Several guides and examples are available to educate and guide health care providers, decision makers, 
insurers, and pharmacists about how pharmacists and other health care providers can better serve 
patients through CPAs and CDTM. Examples include the following:
• Collaborative Practice Agreements and Pharmacists’ Patient Care Services: A Resource for Pharmacists.7
• A Resource for Nurses, Physician Assistants, and Other Providers.8
• A Resource for Government and Private Payers.9
• A Program Guide for Public Health: Partnering with Pharmacists.10
• Agency for Healthcare Research and Quality, Pharmacy Quality Alliance.11
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Self-Measured Blood Pressure 
Monitoring With Clinical Support
Self-measured blood pressure monitoring (SMBP) involves a patient’s regular use of 
personal blood pressure monitoring devices to assess and record blood pressure across 
different points in time outside of a clinical or community or public setting, typically at 
home.1,2 When combined with clinical support (e.g., one-on-one counseling, web-based or 
telephonic support tools, education), SMBP can enhance the quality and accessibility of care 
for people with high blood pressure and improve blood pressure control.3
Summary
SMBP with clinical support 
involves training patients to 
regularly monitor and record 
their own blood pressure at home 
with a personal device and rely 
on clinical support as needed. 
SMBP is a cost-effective strategy 
for lowering blood pressure and 
increasing medication adherence.
Stories From the Field:  
Millgrove Medical Center 
(Norristown, Pennsylvania).
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Evidence of Effectiveness
The evidence base for implementing SMBP in health care systems and practices is very strong. Studies demonstrate internal and 
external validity, and there has been independent replication with positive results. Several studies show the positive effect of 
SMBP in improving blood pressure control. Comprehensive implementation guidance is available to facilitate the adoption of this 
strategy by health care systems and practices.
Evidence of Impact
Health Impact
SMBP has proven useful in reducing 
the risk of death and disability 
associated with hypertension.4,5 
The research literature has 
shown that, when combined 
with additional clinical support, 
SMBP is effective in reducing 
hypertension, improving patient 
knowledge, improving the health 
system process, and enhancing 
medication adherence.2 SMBP has 
also been associated with patient 
empowerment, autonomy, self-
efficacy, and lifestyle modification.
Health Disparity Impact
Evidence is insufficient to show that 
SMBP affects health disparities. Some 
of this lack of evidence is related to 
minorities being underrepresented in 
comparative studies.2 In current studies, 
some findings show that SMBP failed 
to improve blood pressure control for 
a largely minority, urban population 
of Hispanics and people without 
insurance, a population which is largely 
understudied.6 A statistically significant 
difference in systolic blood pressure was 
found for white participants who used 
SMBP, but not for African Americans or 
Hispanics. Studies note the potential 
negative effect of barriers to SMBP 
for low-income and minority groups. 
For example, while validated blood 
pressure monitors for home use are 
generally considered affordable, the 
lack of reimbursement for these devices 
and additional out-of-pocket costs can 
be barriers for low-income populations.
Economic Impact
Economic evidence from a review by 
the Community Preventive Services Task 
Force indicates that SMBP monitoring 
strategies are cost-effective when 
combined with additional clinical 
support or within a team-based care 
model.7 The median cost per quality-
adjusted life year (QALY) gained 
over a 20-year period for SMBP with 
additional support was $2,832 or $4,046, 
depending on the QALY conversion 
method used.7 The median cost per 
QALY gained for SMBP as part of team-
based care was $7,585 or $10,923.7 SMBP 
has been found to be cost-beneficial for 
insurers, with an estimated net savings 
associated with the use of home blood 
pressure monitors ranging from $33 to 
$168 per member in the first year and 
from $420 to $1,380 per member over 10 
years.8 The return on investment (ROI) for 
the insurer ranges from $0.85 to $3.75 
per $1 invested in the first year and from 
$7.50 to $19.34 per $1 invested over 10 
years. Because of the clear financial and 
health benefits of SMBP, experts from the 
American Heart Association, American 
Society of Hypertension, and Preventive 
Cardiovascular Nurses Association 
recommend that payers cover the costs 
of home blood pressure monitors, 
patient training in SMBP techniques, and 
clinical support.3
SMBP has proven useful in 
reducing the risk of death and 
disability with hypertension.
Stories from the Field
Self-Measured Blood Pressure
SMBP at Millgrove Medical Center
The family practice of Dr. Nilesh V. Patel at Millgrove Medical Center in Norristown, 
Pennsylvania, serves 5,300 adult patients in eastern Pennsylvania and is a 
2013 Million Hearts Hypertension Control Champion. The practice achieved 
successful outcomes using SMBP by training patients to monitor and record 
their blood pressure with a blood pressure cuff at home and then transferring 
these measurements to the patients’ electronic health record (EHR). By using 
SMBP and EHRs and including pharmacists in a team-based care approach, the 
practice increased the blood pressure control rate for its patients from 83.4% to 
94.9% in 1 year. This improvement translates to an additional 49 patients who 
are reaching their target blood pressure and significantly reducing their risk of 
cardiovascular disease.
For more information:
Website: www.millgrovemedical.com
Phone: 610-666-1400
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Four Considerations for Implementation
1 Settings
SMBP efforts have been implemented in many clinical and community settings, including FQHCs, general 
practices, YMCAs, and Veterans Affairs medical centers.
2 Policy and Law-Related Considerations
Insurance coverage for SMBP is not universal, but varies by state and individual insurance plans. 
Coverage can vary by SMBP components (e.g., blood pressure measurement devices, clinical support, 
training). Traditional fee-for-service models often reimburse only for office-based visits and services. 
More information on coverage under Medicare and Medicaid can be found online and through Million 
Hearts resources.3 When not covered by insurance, health care flexible spending accounts have been 
recommended to cover the costs of home blood pressure monitors.
3 Implementation Guidance
Through the Million Hearts® initiative, CDC has created a series of translation guides on SMBP for public 
health practitioners and clinicians. The Million Hearts website also has an SMBP webpage, which has 
resources, evidence, tools, and information about effective SMBP practices. See these links for more 
information on implementation:
• Self-Measured Blood Pressure Monitoring: Action Steps for Clinicians.3
• Self-Measured Blood Pressure Monitoring: Action Steps for Public Health Practitioners.9
• Self-Measured Blood Pressure Monitoring by Million Hearts.10
4 Resources
Several federal agencies and initiatives provide resources related to the use of SMBP, including:
• Community Preventive Services Task Force.11
• US Preventive Services Task Force.12
• Centers for Disease Control and Prevention’s 6|18 Initiative.13
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Self-Management Support  
and Education
Self-management involves focusing on an individual’s role in managing chronic disease. This 
term is often associated with self-care and includes an array of activities needed to effectively 
manage one or more chronic conditions.1 Self-management support and education is defined 
as assistance provided by clinicians and public health practitioners to enhance an individual’s 
self-efficacy in managing one or more chronic conditions. This assistance can include activities 
such as patient education, support for lifestyle modifications, and support to help individuals 
develop the skills needed for effective chronic disease management.1,2
Evidence of Impact
Health 
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Summary
Self-management support and 
education provided to patients 
by clinicians and public health 
practitioners is an effective 
strategy for improving patient 
knowledge and self-efficacy, 
lowering blood pressure, and 
increasing medication adherence.
Stories From the Field: 
ThedaCare (Wisconsin).
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Evidence of Effectiveness
The evidence base for implementing self-management support and education for people with chronic disease, including those 
with hypertension, in health care systems and practices is very strong. Studies demonstrate internal and external validity, and 
there has been independent replication with positive results. Several studies have been conducted and show the positive effect 
of self-management support and education in improving blood pressure control. However, limited implementation guidance is 
available to help health care systems and practices adopt this strategy.
Evidence of Impact
Health Impact
Self-management support 
and education has been linked 
specifically to positive cardiovascular 
outcomes, including lowered blood 
pressure, increased hypertension-
related knowledge, and enhanced 
competence in hypertension self-
management behaviors.1–4 Research 
has also shown that self-management 
support and education can improve 
medication adherence, self-efficacy, 
self-rated health, cognitive symptom 
management, frequency of aerobic 
exercise, and depression.5 
Self-management programs have 
been effective among both white and 
African American participants, but 
studies note the need to further test 
programs among other racial and ethnic 
populations. Certain components of self-
management support and education 
may be more important in rural and 
low-income settings, where health care 
resources may be limited, but this issue 
has not been looked at in-depth and 
deserves further exploration.6
Health Disparity Impact Economic Impact
The costs of chronic disease self-
management programs vary 
depending on the strategy and 
program components used. 
Hypertension self-management 
education programs that use 
strategies beyond SMBP can be 
cost-effective.7 Chronic disease 
self-management programs can 
potentially be cost-saving. For 
example, one self-management 
education program was estimated 
to save health systems $394 per 
participant per year, and it has been 
estimated that health systems could 
save $3.9 billion nationally if 5% of 
adults with one or more chronic 
conditions were reached.8 More 
research that uses actual cost data 
rather than modeled estimates is 
needed to confirm these findings.
Self-management support 
and education has been 
linked specifically to positive 
cardiovascular outcomes.
Stories from the Field
Self-Management Education
Self-Management Education at ThedaCare
ThedaCare health care system serves 100,357 adult patients in northeast 
Wisconsin. ThedaCare is a 2013 Million Hearts® Hypertension Control Champion 
that has successfully implemented a self-management program to help adults 
with hypertension learn self-management skills. Patients in the ThedaCare 
Physicians program are given educational materials on nutrition, exercise, 
hypertension medication, health problems associated with hypertension, and 
smoking cessation. When they complete the program, patients receive a free 
home blood pressure monitor. After implementing the program, ThedaCare 
reported steady improvement among patients with uncomplicated hypertension. 
From 2012 to 2013, the blood pressure control rate among ThedaCare patients 
increased by 1.4% (81.6% to 83.0%), which equates to 23,136 of ThedaCare’s 
27,879 patients with high blood pressure having this condition under control. 
ThedaCare’s success is attributed to having strong leadership support and a 
provider champion for the program.
For more information:
Website: www.thedacare.org
Phone: 920-831-180
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Four Considerations for Implementation
1 Settings
Self-management support and education has been implemented in several community and clinical 
settings, including YMCAs, federally qualified health centers (FQHCs), and managed care health systems.
2 Policy and Law-Related Considerations
In 2016, the Centers for Medicare & Medicaid Services (CMS) finalized regulations for the Cardiac 
Rehabilitation Incentive Payment Model, which reimburses for cardiac rehabilitation services, including 
self-management support and education, in selected geographic areas. This regulation covers 
beneficiaries hospitalized for a heart attack or bypass surgery. More information about this regulation can 
be found on CMS’s Cardiac Rehabilitation Incentive Payment Model website.
3 Implementation Guidance
Health departments can link patients to self-management programs in their communities. One tool 
developed to help patients find self-management educational programs in their communities is a CDC 
resource called Learn More. Feel Better.9
4 Resources
Self-management support and education for chronic disease is widely supported by federal and 
nonfederal initiatives, including CDC’s Million Hearts Initiative.10
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Reducing Out-of-Pocket Costs  
for Medications
Reducing out-of-pocket costs (ROPC) for patients with hypertension and hyperlipidemia 
involves program and policy changes that make medications for cardiovascular disease 
(CVD) prevention more affordable. Costs for medications can be reduced by providing new 
or expanded coverage and lowering or eliminating out-of-pocket payments by patients (e.g., 
copayments, coinsurances, deductibles).1
Summary
Reducing costs on medications 
for patients with hypertension 
and hyperlipidemia is an effective 
strategy for increasing medication 
adherence and lowering blood 
pressure and cholesterol levels 
among diverse populations and 
in various settings.
Stories From the Field: Kaiser 
Permanente Northern California.
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Evidence of Effectiveness
The evidence base supporting the implementation of ROPC strategies to promote medication adherence is very strong. Studies 
examining ROPC for medications have demonstrated strong internal and external validity. A review by the Community Preventive 
Services Task Force concluded that ROPC for medications is effective for increasing medication adherence and results in improved 
health outcomes. Evaluations of ROPC strategies have been replicated with positive results. Unfortunately, no comprehensive 
guidance for implementing ROPC strategies is available.
Evidence of Impact
Health Impact
Evidence shows that ROPC for 
medications for patients with 
hypertension and hyperlipidemia is 
effective in improving medication 
adherence, which results in lower 
blood pressure and cholesterol 
levels. The Community Preventive 
Services Task Force found that ROPC 
for patients taking blood pressure 
and cholesterol medications 
increased medication adherence by 3 
percentage points and increased the 
proportion of patients achieving 80% 
adherence by 5.1 percentage points, 
which significantly improved blood 
pressure and cholesterol outcomes.1,2 
Health Disparity Impact
Evidence shows that ROPC for 
medications is an effective strategy 
for men and women and for patients 
from racial and ethnic minority groups. 
ROPC is especially beneficial for low-
income patients, who face the greatest 
financial barriers to taking medications 
as prescribed.2 
Economic Impact
The evidence base for the economic 
benefits of ROPC for medications is 
limited, and findings are inconsistent. 
The Community Preventive Services Task 
Force found that the median intervention 
cost for ROPC for medications was $174 
per person per year. The Task Force’s 
review found that ROPC could reduce 
health care costs, with a median change 
of -$128 per person per year. Health 
care savings could potentially offset 
intervention costs, but evidence on 
net benefits was limited and mixed. 
Therefore, no overall conclusion could 
be reached. More research on cost-
effectiveness is needed.2
ROPC for medications is an 
effective strategy for men and 
women and for patients from 
racial and ethnic minority groups. 
Stories from the Field
Reducing Medication Costs
ROPC at Kaiser Permanente Northern California 
Kaiser Permanente Northern California (KPNC) is a 2013 Million Hearts® Hypertension Control Champion because 
of its hypertension program. The program seeks to improve hypertension control through five key strategies: a 
comprehensive hypertension registry, performance metrics, evidence-based guidelines for treatment, medical 
assistant visits for blood pressure measurement, and single-pill combination pharmacotherapy. Two of the five 
strategies reduced out-of-pocket costs for patients. One eliminated copayments for patients who visited a medical 
assistant for blood pressure monitoring, while the other introduced a less-expensive, single-pill combination 
therapy that combined two medications into one. KPNC reported significant improvements since it began using 
this multicomponent hypertension program. From 2001 to 2013, hypertension control among KPNC’s patients 
increased from 44% to 90%, which translated to more than 200,000 additional patients who had their blood 
pressure under control. Although the success of this program could not be attributed to any one component 
alone, ROPC for medications likely played an important role, as prescription rates for hypertension drugs increased 
significantly after the introduction of the single-pill combination therapy.
For more information:
Marc G. Jaffe, MD
Department of Endocrinology, Kaiser Permanente South San Francisco Medical Center
E-mail: marc.jaffe@kp.org
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Four Considerations for Implementation
1 Settings
Strategies to reduce ROPC for medications can be implemented by health care providers and plans, 
government agencies, and employers who offer insurance plans to their employees.1
2 Policy and Law-Related Considerations
Policies or programs to reduce or eliminate out-of-pocket costs for medications can be coordinated and 
implemented through health care systems, partnerships, and health care providers or insurance plans. 
One ROPC policy approach is to reduce or eliminate copayments for generic medications. Providers 
may need to discuss appropriate generic medications with their patients.1 Many states have statutory 
or regulatory requirements that (1) require Medicaid providers to use generics first and (2) require or 
authorize pharmacists to switch Medicaid patients to an equivalent generic drug if a brand name drug is 
prescribed.5
3 Implementation Guidance
Direct implementation guidance for ROPC was not readily available at the time of this publication. 
Collaboration between public insurance plans, such as Medicare and Medicaid, and private insurance 
plans should be considered to promote use of these strategies.
4 Resources
ROPC for medications is a strategy that is supported by several federal initiatives, including: 
• CDC’s 6|18 Initiative.3
• CDC’s Medication Adherence Action Guide.4
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Implementing Clinical Decision 
Support Systems 
Clinical decision support systems (CDSS) are computer-based programs that analyze data 
within EHRs to provide prompts and reminders to assist health care providers in implementing 
evidence-based clinical guidelines at the point of care. Applied to cardiovascular (CVD) 
prevention, CDSS can be used to facilitate care in various ways—for example, by reminding 
providers to screen for CVD risk factors, flagging cases of hypertension or hyperlipidemia, 
providing information on treatment protocols, prompting questions on medication adherence, 
and providing tailored recommendations for health behavior changes.
Summary
CDSS involves the use of 
computer-generated reminders 
and prompts to help health care 
providers make clinical decisions. 
It is an effective strategy for 
increasing the quality of care in 
screening, testing, and treating 
patients with high blood pressure 
and high cholesterol. Evidence 
that it directly affects health 
outcomes is lacking.
Stories From the Field: South 
Omaha Medical Associates, 
Nebraska Department of Health 
and Human Services, Douglas 
County Health Department, and 
Wide River Health Information 
Technology.
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Evidence of Effectiveness
The evidence base demonstrating the effectiveness of CDSS is very strong. Research studies that examined CDSS had strong 
internal and external validity, the Community Preventive Services Task Force concluded that CDSS is effective, and CDSS trials have 
been replicated with positive results. Implementation guidance on CDSS is available from several sources.
Evidence of Impact
Health Impact
A review by the Community Preventive 
Services Task Force found that CDSS 
leads to significant improvements 
in the following three quality of care 
practices for CVD prevention delivered 
by health care providers:1,2
• Recommendations for screening 
(e.g., for blood pressure or 
cholesterol) and other preventive 
care (e.g., smoking cessation).
• Evidence-based clinical tests 
related to CVD.
• CVD-related treatments prescribed.
Evidence exists that CDSS can be 
tied to lower blood pressure and 
cholesterol levels, but the findings on 
this association are inconsistent.
Health Disparity Impact
The ability of CDSS to reduce health 
disparities is understudied, and 
several researchers have suggested 
that further work is needed to directly 
examine this issue. Some have 
noted that providers working with 
underserved communities typically 
lag behind in the uptake of electronic 
health records (EHRs) and CDSS, and 
evidence exists that CDSS leads to 
successful health outcomes when 
used in underserved communities.3,4 
Thus, it is reasonable to conclude that 
CDSS has the potential to eliminate 
barriers and reduce disparities in 
hypertension-related care.
Economic Impact
Economic factors related to the 
implementation and maintenance 
of CDSS have not been well-
documented. A review by the 
Community Preventive Services Task 
Force was inconclusive because of 
a lack of available data. The Task 
Force found that current studies 
are extremely heterogeneous in 
the range of CDSS functions and 
CVD risk factors studied and in the 
completeness or inclusion of major 
cost factors. Thus, the ability to 
determine an overall estimate of the 
cost or economic benefit of CDSS 
is limited. Of the studies available, 
health care costs appear to be more 
likely to decrease than increase 
after CDSS implementation, but the 
usefulness of this evidence is limited 
by incomplete and inconsistent data.5 
More data on the complete costs 
of developing, implementing, and 
operating CDSS systems are needed 
to fully assess its cost-effectiveness or 
return on investment.
The evidence base demonstrating the 
effectiveness of CDSS is very strong.
Stories from the Field
Clinical Decision Support
CDSS at South Omaha Medical Associates
South Omaha Medical Associates (SOMA) is a family-owned, family-operated clinic that is centrally located in 
South Omaha, Nebraska. It has a higher percentage of low-income patients than clinics in surrounding areas. 
SOMA collaborated with the Nebraska Department of Health and Human Services, Douglas County Health 
Department, and Wide River Health Information Technology to assess its technology needs and make plans to 
implement CDSS. As a result of this assessment, the clinic increased its use of EHRs and implemented systems 
to better identify patients with undiagnosed hypertension, increase use and monitoring of clinical quality 
measures, and increase use of clinically supported self-measured blood pressure monitoring. These changes 
improved workflow at the clinic and led to a 25% increase in patient visits since the start of the collaboration. In 
addition, Blue Cross Blue Shield awarded SOMA its Blue Distinction Award for meeting overall quality measures 
for patient safety and outcomes.
For more information:
Chronic Disease Prevention and Control Program
Nebraska Department of Health and Human Services
301 Centennial Mall South
Lincoln, NE 68509
E-mail: CVHProgram@dhhs.ne.gov
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Four Considerations for Implementation
1 Settings
Although CDSS has been implemented in a wide variety of health care settings, most published research 
has been within the context of primary outpatient care.
2 Policy and Law-Related Considerations
Legal considerations for CDSS begin with the vendors who interpret and translate guidelines into 
algorithms used by these systems. Vendors must fully disclose the sources used to build the knowledge 
base for their software and any limitations or weaknesses of the software. Providers must ensure that 
CDSS programming is updated regularly to account for changes in evidence and guidelines, and that 
EHRs associated with CDSS include complete and up-to-date information about patients’ medical 
histories and allergies.1,8,13 Provider fatigue or avoidance of CDSS guidance has been raised as a barrier to 
successful outcomes, leading to suggestions that initial and repeat trainings be a mandatory part of CDSS 
implementation.
3 Implementation Guidance
Implementation guidance for CDSS is available from various sources. The following resources may be 
particularly useful:
• Measure Up Pressure Down: Provider Toolkit to Improve Hypertension Control from the American 
Medical Group Foundation.6
• Clinical Decision Support (CDS) Implementation: How-To Guides for CDS Implementation from 
HealthIT.gov.7
• Castillo RS, Kelemen A. Considerations for a successful clinical support system. CIN: Computers, 
Informatics, Nursing.8
4 Resources
CDSS is supported and promoted by many federal initiatives and agencies, including:
• CDC’s Million Hearts Initiative.9
• Office of the National Coordinator for Health Information Technology.10
• CMS’s Merit-Based Incentive Payment System: Advancing Care Information.11
• Agency for Healthcare Research and Quality.12
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Domain 4:
 
Effective Strategies in 
Community Programs 
Linked to Clinical Services
Community programs linked to clinical 
services, also called community-clinical links, 
connect community programs with health systems to improve chronic disease 
prevention, care, and management. Effective links can reduce barriers to care and 
increase patient adherence to clinician recommendations.
Integrating Community 
Health Workers on 
Clinical Care Teams and 
in the Community
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Integrating Community Health
Workers on Clinical Care Teams
and in the Community
A community health worker (CHW) is defined as a frontline public health worker who is a 
trusted member of a community or who has a thorough understanding of the community 
being served.1 This relationship allows CHWs to serve as a link between health and social 
service programs and the community to promote access to services and improve the quality 
and cultural competence of service delivery. CHWs also help build individual and community 
capacity to improve health outcomes by increasing health knowledge and self-sufficiency 
through a range of activities, such as outreach, community education, informal counseling, 
social support, and advocacy. The integration of CHWs on clinical care teams is a strategy 
that can be considered to straddle both Domains 3 (health care system interventions) and 4 
(community-clinical links).
Summary
Integrating CHWs on clinical care 
teams and in the community 
is an effective strategy for 
increasing patient knowledge 
and medication adherence and 
lowering blood pressure and 
cholesterol levels among diverse 
populations and in various 
settings.
Stories From the Field:   
Clinical-Community Health 
Worker Initiative, Mississippi State 
Department of Health.
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Evidence of Effectiveness
The evidence base demonstrating the effectiveness of integrating CHWs on clinical care teams is very strong. Research studies 
examining this intervention have had strong internal and external validity, the Community Preventive Services Task Force 
concluded that the integrating CHWs on clinical care teams is effective, and trials of interventions that integrated CHWs have been 
replicated with positive results. Implementation guidance for integrating CHWs on clinical care teams is available from  
several sources.
Evidence of Impact
Health Impact
Integrating CHWs on clinical care 
teams or in the community as part 
of cardiovascular disease (CVD) 
prevention programs can help 
program participants lower their 
blood pressure, cholesterol, and 
blood sugar levels; reduce their CVD 
risks; be more physically active; and 
stop smoking.2 It can also improve 
patient knowledge and adherence 
to medication regimens and 
improve health care services.2
Health Disparity Impact
By design, the CHW model seeks to 
eliminate health disparities because 
the populations served usually include 
people who have more barriers to care.3 
A Community Preventive Services Task 
Force review found that most studies 
on CHWs focused on underserved 
populations and concluded that 
the CHW model can be effective in 
improving health and reducing health 
disparities related to CVD.2
Economic Impact
A review by the Community Preventive 
Services Task Force concluded that 
interventions that integrate CHWs on 
clinical care teams to prevent CVD are 
cost-effective.2 The median cost of 
intervention was $329 (range: $98 to 
$422) per person per year, with the main 
cost drivers being CHW time, costs for 
training and supervision of CHWs, and 
cost for any additional interventions or 
staff. The median change in health care 
costs after a CHW intervention was a 
reduction of $82 (range: -$415 to $14) 
per person per year.
One well-designed study found a return 
on investment of 1.8 to 1 for a large 
health plan that served an underserved 
urban population. Overall evidence for 
an estimated net benefit indicated that 
health care cost savings did not exceed 
the cost of intervention (median net 
benefit: -$311 from seven studies). The 
median cost per quality-adjusted life 
year (QALY) saved was $17,670 (range: 
$8,233 to $24,149), and all estimates 
were well below the commonly used and 
conservative threshold of $50,000 per 
QALY. The review also noted incomplete 
reporting or inclusion of major cost 
drivers in some studies. Future studies 
should assign a cost to CHW services 
and time, whether those services are 
voluntary (unpaid) or otherwise.2
Stories from the Field
Community Health Workers
CHWs at Mississippi Delta Health Collaborative
The Mississippi Delta Health Collaborative implemented the Clinical-Community Health Worker 
Initiative (CCHWI) to improve clinical outcomes for CVD through aspirin use, hemoglobin 
A1c control, blood pressure control, cholesterol management, and smoking cessation in the 
18-county Mississippi Delta region.13 The CCHWI model emphasizes the importance of CHWs as 
integral members of clinical care teams. CHWs received 160 hours of core competency training 
and 40 hours of training specific to CVD prevention. About 1,100 patients from six participating 
health care systems—including FQHCs, Rural Health Centers, and private providers—were 
enrolled because they were diagnosed with hypertension, diabetes, or dyslipidemia. After 4 
years, seven CHWs were integrated into the participating health care systems and their duties 
included visiting patients in their homes. CHWs worked to meet patients’ health care needs 
through chronic disease self-management workshops, trainings on self-measured blood 
pressure monitoring, and encouragement of medication adherence. From 2012 to 2016, a 
1.3% relative decrease in systolic blood pressure and a 1.7% relative decrease in diastolic blood 
pressure were observed among patients with hypertension who were enrolled in this program. 
For more information:
Tameka Walls, Bureau Director, Mississippi State Department of Health 
E-mail: Tameka.Walls@msdh.ms.gov
Websites: http://msdh.ms.gov/msdhsite/ and www.cdc.gov/dhdsp/docs/field_notes_clinical_
community_health_worker.pdf
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Four Considerations for Implementation
1 Settings
CHWs have been integrated in a variety of primary care settings, including federally qualified health centers 
(FQHCs), managed care health systems, patient-centered medical homes, and community pharmacies.1–5
2 Policy and Law-Related Considerations
The need for policies to ensure that CHWs are sustainably reimbursed for their contribution to team-
based care is a frequently cited concern.1,3,4 There is also debate about whether states should require 
credentialing or certification of CHWs. Proponents of credentialing would like policies to support the 
consistency of training and certification of CHWs across the country. Opponents are concerned that 
credentialing could reduce the CHW workforce and decrease access to CHWs who may have intrinsic and 
invaluable qualities that cannot be certified or credentialed. More information is available from CDC in the 
form of a State Law Fact Sheet11 and Policy Evidence Assessment Report12 that address this topic. 
3 Implementation Guidance
CDC has compiled evidence-based research to support the effectiveness of CHWs in the Community 
Health Worker Toolkit.6 This tool kit also includes information that state health departments can use to 
train and further build capacity for CHWs in their communities, as well as helpful resources that CHWs can 
use in their communities.
4 Resources
Many public and private institutions support including CHWs on health care teams. Examples include the 
following:
• Centers for Disease Control and Prevention’s 6|18 Initiative.7
• CDC’s Million Hearts Initiative.8
• The Institute of Medicine and National Academies Press.9
• Centers for Medicare & Medicaid Services.10
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Community Pharmacists and Medication 
Therapy Management
Medication therapy management (MTM) is a distinct service or group of services provided 
by health care providers, including pharmacists, to ensure the best therapeutic outcomes for 
patients. MTM includes five core elements: medication therapy review, a personal medication 
record, a medication-related action plan, intervention or referral, and documentation and 
follow-up. Within the context of cardiovascular disease (CVD) prevention, MTM can include 
a broad range of services, often centering on (1) identifying uncontrolled hypertension (2) 
educating patients on CVD and medication therapies, and (3) advising patients on health 
behaviors and lifestyle modifications for better health outcomes. MTM is especially effective 
for patients with multiple chronic conditions, complex medication therapies, high prescription 
costs, and multiple prescribers. MTM can be performed by pharmacists with or without a 
collaborative practice agreement (CPA), and it is a strategy that can be considered to straddle 
both Domains 3 (health care system interventions) and 4 (community-clinical links).
Summary
MTM is care provided by 
pharmacists with the goal of 
ensuring the most effective use  
of drug therapy. It is a cost-
effective strategy for increasing 
patient knowledge and 
medication adherence and 
lowering blood pressure.
Stories From the Field:  
Ohio Department of Health.
Evidence of Impact
Health 
Impact
Health 
Disparity 
Impact
Economic 
Impact
Legend: Supported Moderate Insufficient
Evidence of Effectiveness
Effect Implementation Guidance
Research 
Design
Internal 
Validity
Independent
Replication
External & 
Ecological 
Validity
Legend: Well supported/
Supported
Promising/
Emerging
Unsupported/
Harmful
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Evidence of Effectiveness
Strong evidence exists that the use of MTM by pharmacists is effective. Although the exact combination of MTM activities tends 
to vary between settings, studies examining MTM have generally found it to be effective and to have strong internal and external 
validity. MTM trials have been replicated in many different contexts with positive results. Implementation guidance on MTM is 
available from several sources, including the guidance provided under Medicare Part D.
Evidence of Impact
Health Impact
In 2015, the Agency for Healthcare 
Research and Quality (AHRQ) found the 
evidence behind MTM to be insufficient 
because of inconsistency in the 
operationalization of MTM across studies, 
but concluded that MTM can improve 
medication adherence.1 MTM has been 
shown to be effective for lowering systolic 
and diastolic blood pressure; lowering LDL 
cholesterol and other health indicators 
(e.g., glycosylated A1C, HBA1c); increasing 
patient knowledge; improving patient 
quality of life and medication adherence; 
and improving the safe and effective 
use of medications, including reducing 
therapeutic duplication, decreasing total 
medications prescribed, and increasing 
adherence for therapeutic care.2–8
Health Disparity Impact
Expanding the pharmacist’s role 
through MTM is likely to increase 
access to health care for populations 
facing the most barriers to care. 
However, few studies have examined 
the ability of MTM to reduce health 
disparities in CVD outcomes. Although 
some evidence exists that MTM can 
achieve positive outcomes among 
minority and low-income populations, 
the extent of this evidence is limited 
and inconsistent.4,5 More research is 
needed to directly examine the effect 
of MTM on different populations.
Economic Impact
Studies have indicated that MTM 
can produce health care cost savings 
and a positive ROI for health care 
systems.9–11 A study that examined 
the effect of providing MTM in a 
large health system for over 10 years 
found that the cost to providing 
MTM services was $76 per patient 
encounter, and the return on 
investment (ROI) that resulted from 
health care cost savings was $1.29 
per $1 spent on MTM services over 
this period.10
Another study that evaluated 
the use of MTM by a self-insured 
employer reported an intervention 
cost of $145.61 per patient and a 
ROI to the payer of $1.67 per $1 of 
MTM costs over a 6-month period.11 
Despite early findings of potential 
economic benefits, recent meta-
analyses and systematic reviews 
have identified a need for better 
cost-effectiveness data on expanded 
pharmacist care.7,8
Strong evidence exists 
that the use of  MTM by 
pharmacists is effective.
Stories from the Field
Medication Therapy Management
MTM  at Ohio Department of Health
In 2014, the Ohio Department of Health (ODH) teamed up with three 
Federally Qualified Health Centers (FQHC) sites to assess the effect of MTM 
counseling sessions on patients with hypertension. This effort involved 
collaboration among the Ohio State University College of Pharmacy, 
Ohio Pharmacists Association, Ohio Association of Community Health 
Centers, and the Health Services Advisory Group. These partners helped 
plan and develop the assessment. Pharmacists administered MTM to 
5,000 patients with hypertension who were receiving care at one of the 
three FQHC sites. After 6 months, assessments found that hypertension 
control had increased to 68.6% among these patients. There were key 
components related to the project’s achievement, which included 
maintaining relevant partnerships, implementing the pilot in one type 
of pharmacy setting, allowing FQHC sites to develop their own protocols 
for patient enrollment, using effective dissemination processes, and 
selecting data points that align with current pharmacy practices. 
Challenges included finding champions for the MTM model. 
For more information:
Jen Rodis, Assistant Dean for Outreach and Engagement
Ohio State University College of Pharmacy
E-mail: rodis.2@osu.edu
Website: www.ohiochc.org
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Four Considerations for Implementation
1 Settings
MTM has been implemented in several settings, including federally qualified health centers, patient-
centered medical homes, managed care health systems, community pharmacies, hospital pharmacies, and 
primary care clinics.
2 Policy and Law-Related Considerations
MTM is currently supported under the Centers for Medicare & Medicaid Services (CMS), as a service 
available to selected Medicare beneficiaries. As a part of Medicare Part D regulations, enrollees with 
multiple chronic diseases who are taking multiple Part D drugs are eligible for MTM programs.12 Outside 
of the CMS guidelines, reimbursement for time and services is a key issue for pharmacists performing 
MTM. Regional variations in training and scope of practice can limit pharmacists when they attempt to 
provide MTM services. For MTM to work most effectively, pharmacists and prescribers can develop CPAs 
with shared blood pressure management protocols. Other policy considerations that need attention are 
determining the inclusion criteria for patients to receive MTM and encouraging payers to make the service 
available and offer reimbursement for pharmacists.
3 Implementation Guidance
Implementation guidance has been developed by various organizations, including:
• Centers for Medicare & Medicaid Services.12
• American Pharmacists Association's MTM Central,13 which includes implementation guidance, an MTM 
resource library, and information about the added value of MTM.
4 Resources
Several federal agencies are working on initiatives that focus on greater involvement of pharmacists in 
cardiovascular prevention and MTM. They include the following: 
• Centers for Medicare & Medicaid Services.12
• AHRQ, which provides the National Guideline Clearinghouse14 and a list of resources related to 
innovations in MTM.15
• CDC’s 6|18 Initiative.16
• CDC's Million Hearts Initiative.17
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Appendix B
Appendix B. Rapid Synthesis and Translation 
Process (RSTP)
As part of the process of developing the Best Practices Guide for CVD Prevention, we adapted the Rapid Synthesis and 
Translation Process (RSTP) to provide a structure for engaging both subject matter experts (SMEs) and health care 
practice partners. This conceptual process, developed within CDC’s Division of Violence Prevention in the National 
Center for Injury Prevention and Control, consists of six fundamental steps (Figure 2), which do not necessarily occur in 
chronological order.
The following steps and related definitions are applied in our adaptation of the RSTP framework:
• Step 1: Solicit Topics from End Users — For the Best Practices Guide for CVD Prevention, “end users” were 
grantees (health care practitioners), evaluators (internal), content SMEs (internal and external), and program 
specialists (internal).
• Step 2: Scan Findings — The Best Practices Guide for CVD Prevention development team in CDC’s Division for 
Heart Disease and Stroke Prevention (DHDSP) reviewed the research literature to identify evidence-based 
strategies for preventing cardiovascular disease (CVD). The strategies determined to be potential best practices 
were moved to Step 3.
• Step 3: Sort for Relevance — Criteria for including strategies in the Best Practices Guide for CVD Prevention were 
determined according to an internal vetting process that included division and branch leadership, internal SMEs, 
and external SMEs. A group of grantees was also asked to identify practice-based relevance for each strategy.
• Step 4: Synthesize Results — Internal SMEs used the Continuum of Evidence of Effectiveness to assess the 
evidence behind the identified strategies. This interactive, online tool uses a series of questions about each 
strategy to place it on a continuum of six dimensions of evidence (see Appendix C for more information). 
Once this baseline assessment of the evidence was done, only strategies with results and methodology in the 
highest category (i.e., supported or well-supported) were considered further. The availability of implementation 
guidance was not a requirement for inclusion. Selected strategies were then reviewed for fit with the best 
practices framework to assess their potential to improve cardiovascular health, reduce health disparities, and 
demonstrate economic sustainability.
• Step 5: Translate to End User(s) — A small team in DHDSP used the data collected from the SME assessments, 
the best practice framework review, and additional input from internal program and evaluation experts to draft 
the Best Practices Guide for CVD Prevention.
• Step 6: Review by End User(s) — Standard processes for clearance by CDC and the US Department of Health 
and Human Services were initiated after additional review by a panel of grantees, SMEs, and other potential  
end users.
For more information on the best practices framework, see Spencer LM, Schooley MW, Anderson LA, et al. Seeking 
Best Practices: A Conceptual Framework for Planning and Improving Evidence-Based Practices. Prev Chronic Dis. 
2013;10:130186. doi: http://dx.doi.org/10.5888/pcd10.130186. 
Figure 2. Rapid Synthesis and Translation Process (RSTP)
Step 1: 
Solicit topics from 
end-user(s)
Step 2: 
Scan findings
Step 3: 
Sort for relevance
Step 4: 
Synthesize results
Step 5: 
Translate for end-user(s)
Step 6: 
Review by end-user 
Consult with science 
experts 
Consult with science 
experts 
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Adapted figure from: Thigpen S, Puddy RW, Singer HH, Hall DM. Moving knowledge into action: developing the Rapid Synthesis and Translation 
Process within the Interactive Systems Framework. Am J Community Psychol. 2012;50(3-4):285–294.
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Appendix C. Understanding the Continuum of 
Evidence of Effectiveness Tool 
The Continuum of Evidence of Effectiveness (hereafter called the Continuum) tool clarifies and defines standards for 
assessing research evidence. Because of its ability to determine the strength of evidence on the basis of a clear and 
universal set of standards, the Continuum was chosen as the mechanism to rate the evidence behind the strategies 
included in the Best Practices Guide for CVD Prevention. This interactive, online tool was developed in 2007 by CDC’s 
Division of Violence Prevention in the National Center for Injury Prevention and Control. The division needed a way 
to provide coherent and consistent language around the word “evidence” in programmatic activities. Division staff 
synthesized information about program effectiveness from the research literature, subject matter experts, and 
practitioners with experience implementing strategies in the field. This information guided the development of the 
Continuum, which assesses various components to determine the strength of the best available research evidence on 
a program, practice, or policy. The Continuum also illuminates the strengths and weaknesses of the research evidence 
and offers guidance on next steps for consideration. 
Although this tool was developed to be applied specifically to the field of violence prevention, it can be used to guide 
evidence-based decision making in a wide range of health-related areas. In developing the Best Practices Guide for CVD 
Prevention, two knowledgeable reviewers used this tool to rate the evidence for each strategy considered for inclusion 
in this publication. Any discrepancies between the reviewers’ results were resolved through discussion. 
The structure and range of possible results from the Continuum tool are shown in Figure 3. The Continuum has six 
evidence dimensions, which are listed vertically down the left side of the figure. It has three overarching categories 
of evidence strength, which are listed horizontally across the top of the figure. The Continuum uses the reviewer’s 
input for a specific program or strategy to determine the strength of evidence for each dimension and assign a 
corresponding strength category for each dimension. The full range of responses for each dimension is shown in 
Figure 3. Definitions and possible results for the six dimensions are provided in a table after the figure. 
For more information about the Continuum of Evidence of Effectiveness, see CDC’s 2011 publication, Understanding 
Evidence Part 1: Best Available Research Evidence. A Guide to the Continuum of Evidence of Effectiveness.
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Table 1. Possible Results and Definitions of the Six 
Dimensions of the Continuum of Evidence Effectiveness Tool
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Dimensions and Possible 
Results
Definitions
Effect: The strategy’s ability to reduce cardiovascular disease (CVD) or related risk factors or outcomes.
Found to be effective Prevention strategies that are found to be effective are those that are based on 
sound theory, have been evaluated in at least two well-conducted studies, and have 
demonstrated significant, short-term or long-term preventive effects, depending on 
intent and design.
Some evidence of 
effectiveness
Some programs may not have two or more rigorous evaluations to demonstrate short-
term or long-term preventive effects, but they are based on sound theory and have 
been rigorously evaluated, and the results indicate that they may produce preventive 
outcomes.
Expected preventive effect Some programs may be grounded in theory and have been evaluated with a less 
rigorous design, or they may have been evaluated for short-term or long-term preventive 
effects that are different from the outcomes of interest.
Effect is undetermined Prevention programs that have not been evaluated or that have been evaluated poorly 
(with neither a true nor quasi-experimental design), whether or not they are based 
on sound theory, are considered to have undetermined effectiveness. It is not known 
whether these programs produce short-term or long-term preventive effects.
Ineffective Ineffective strategies are those that have been evaluated in at least two well-conducted 
studies and have demonstrated no significant short-term or long-term outcomes in 
these evaluation studies.
Practice constitutes risk of 
harm
A prevention strategy is considered to be harmful if there is an indication that it causes 
harmful outcomes. This includes short-term outcomes, long-term outcomes, and/or 
unexpected outcomes. These harmful outcomes may be due to the inherent nature of 
the program, its implementation, an interaction with certain population-related factors, 
or an interaction with certain context/setting-related factors.
Internal Validity: The extent to which the short-term and long-term outcomes of a strategy can truly be attributed to the 
strategy itself.
True experimental design True experiments are considered highest in internal validity because participants 
are randomly assigned to the treatment and control conditions. This helps assess 
whether the program, practice, or policy is likely responsible for changes in outcomes 
or if something else could be causing them. The strongest experimental designs also 
have multiple measurement points. These experiments are able to measure not only 
differences in outcomes between treatment and control groups, but also changes in 
outcomes over time. This helps to assess whether the demonstrated effects are sustained 
over time.
Quasi-experimental design Quasi-experiments are also considered to have high internal validity, although less so 
than true experiments. Quasi-experiments are based on sound theory and typically have 
comparison groups (but no random assignment of participants to condition) and/or 
multiple measurement points.
Some quasi-experimental designs are used to evaluate policy changes or naturally 
occurring experiments. These evaluations may not have a comparison group but include 
multiple waves of observation both before and after the introduction of a treatment.
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Nonexperimental design Relative to experimental and quasi-experimental designs, nonexperimental studies are 
the weakest of the three in terms of internal validity. Even though these designs are not 
as rigorous as true and quasi-experiments, they may still be based on sound theory and 
include some empirical aspects geared toward internal validity. Nonexperimental studies 
do not have a control or comparison group or multiple measurement points, making it 
difficult to attribute observed changes to the program.
Sound theory only Prevention programs based on sound theory only are also unable to establish or 
attribute observed changes to the program as those based on experimental or quasi-
experimental studies. These programs are often exploratory in nature and are rooted 
in well-established research and subject matter expert opinion, suggesting that the 
program and/or its components may modify known risk or protective factors and 
produce preventive outcomes.
No research, no sound theory Programs not based on research or sound theory are considered weakest of all in terms 
of establishing an empirical link to a preventive outcome. In the absence of research or 
sound theory, there is no evidence to suggest that they are likely to modify known risk/
protective factors or produce preventive outcomes.
Some, however, may have face validity. This type of validity is concerned with how a 
measure or procedure appears and whether it seems reasonably well designed and 
reliable. Unlike other forms of validity, face validity does not depend on established 
theories for support.
Research Design: The soundness of individual research method components.
Randomized control trial and 
meta-analysis or systematic 
review
Randomized control trials are true experiments and considered a highly rigorous 
research design. They are the strongest research design for establishing a cause-effect 
relationship. Randomized control trials have a control group and randomly assign 
participants to the control or treatment condition.
Systematic reviews collect information from a number of scientific studies on a specific 
topic for the purpose of summarizing, analyzing, and interpreting the overall scientific 
findings on that topic.
A meta-analysis is a type of systematic review that uses statistical analyses to combine 
and analyze the data from single scientific studies on a specific topic and uses these 
combined findings to generate a single estimate or effect size to make more conclusive 
statements about the topic. The strongest reviews are conducted independently, consist 
of studies that were conducted independent from one another, consist of studies that 
are comparable, and include some form of empirical analysis to draw broader, general 
conclusions about the effectiveness of a strategy.
Quasi-experimental design If a design uses multiple groups without random assignment or includes multiple 
measurement points, it is considered quasi-experimental. Quasi-experimental designs 
are considered rigorous designs, although not as rigorous as randomized control trials 
because participants are not randomly assigned to treatment and control conditions 
and may not be equivalent from the start. In this respect, they are weaker in controlling 
threats to internal validity than randomized control trials.
Single group design The single group design is not considered as rigorous as the randomized control trial or 
quasi-experimental designs because it does not include a control or comparison group. 
Single group designs may also have just one post-measure or they may include pre- and 
post-measures.
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Exploratory studies Exploratory studies are focused on learning about a program and the phenomena it 
addresses. Exploratory studies are based on sound theory derived from prior research 
and/or knowledge from subject matter experts. The information gleaned from an 
exploratory study may point to risk and protective factors that are potentially important 
to consider in developing or refining a prevention strategy or its components. Some 
descriptive and observational studies may also be considered exploratory studies.
Anecdotal or needs 
assessment
Studies not based on empirical research or sound theory are the weakest with respect to 
research design. Studies that are based on anecdotal information, needs assessments, or 
windshield surveys are examples of this kind of research.
Independent Replication: Implementation and evaluation of a program by researchers or practitioners who were 
unaffiliated with the original program and who do not have any known conflicts of interest.
Program replication with 
evaluation replication
Programs that demonstrate the most reliability (ability to repeatedly produce the 
preventive effects) are those that have been replicated at least once by independent  
researchers or practitioners, in a similar setting to the original program, using a rigorous 
research design, and with high fidelity to the original program.
Program replication without 
evaluation replication
Programs that demonstrate some reliability are those implemented with high fidelity 
to the original program and in settings that are similar to the setting of the original 
program. These replications may or may not be conducted by independent researchers/
practitioners. Finally, these replications have not been evaluated in the same way as the 
original evaluation of the program.
Partial program replication 
without evaluation replication
Programs that demonstrate weak reliability are those that are partially replicated 
and have not been evaluated. These replications may or may not be conducted by 
independent researchers/practitioners. Programs that are the weakest in reliability are 
those that are not replicated at all since there is no way to measure their reliability.
Possible program replication 
with or without evaluation 
replication
If a program demonstrates harmful effects, it should not be replicated. In some cases, 
harmful effects may not have occurred during the original implementation of a 
prevention strategy but may occur in its replication. Evaluations may or may not have 
been conducted of this replication since a formal evaluation is not needed to prove 
harm. Once harmful effects have been associated with a program, either in the original or 
during a replication, no subsequent replications should be conducted.
Implementation Guidance: The availability of any and all services or materials that could help in the implementation of 
a strategy in different settings.
Comprehensive Comprehensive guidance is the most effective way of ensuring that a program is carried 
out with fidelity in a different setting. This entails availability and accessibility of any 
products, services, or activities that facilitate proper implementation in a new setting. 
These products and services include training, coaching, technical assistance, support 
materials, organizational/systems change consultation, and manuals/guides, and may be 
offered by the program’s developers or some other entity.
Partial For some programs, there may be some products, services, or activities to help 
researchers/practitioners implement them in different settings, but they may be limited 
in their availability and accessibility. It is important to note that since implementation 
support and guidance are limited for these programs, there is a chance that 
implementation issues may be influencing outcomes.
None Programs that do not have any products, services, or activities available to help 
researchers/practitioners implement them in a different setting run a high risk of 
experiencing implementation issues. This also means there is a significant chance that 
implementation issues may be influencing outcomes.
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External and Ecological Validity: Whether a program has been evaluated among diverse populations and in different 
contexts.
Two or more applied studies: 
different settings
Programs that demonstrate the highest external and ecological validity are those that 
have been implemented in two or more applied (“real-world”) settings that are distinct 
from both the original setting and each other in terms of their populations and physical/
geographical locations.
Two or more applied studies: 
same settings
Some programs have been implemented in two or more applied (“real-world”) settings 
that are similar to one another with similar populations. These prevention strategies 
demonstrate moderate external and ecological validity although not as much  
as those implemented in two or more settings that are different and that have 
different populations.
Real-world–informed Programs that have not been implemented in applied settings may still demonstrate 
some external and ecological validity if they are made up of components that are 
consistent with an applied setting. Likewise, programs may demonstrate external  
and ecological validity if they are implemented in ways that mirror conditions of the 
“real-world.”
Somewhat real-world–
informed
Some programs have not been implemented in applied settings and are not structured 
and implemented in ways that are completely consistent with an applied setting. These 
prevention strategies demonstrate some external and ecological validity if some of their 
components and implementation approximate conditions in the “real world.”
Not real-world–informed Programs that demonstrate the least amount of external and ecological validity are 
those whose basic components are not consistent with an applied setting and are not 
implemented in ways that mirror conditions of the “real world.” While it is not known 
whether these programs will be effective in applied settings, there is no way to measure 
which aspects work well across different settings and populations or which aspects are 
setting-specific.
Possible applied studies in 
similar or different settings
Programs that demonstrate harm in any kind of a setting, applied or otherwise, are 
considered harmful. In other words, the program is considered harmful regardless of 
whether or not it has been conducted in an applied setting.
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Appendix D. Glossary
Best practice: A practice supported by a rigorous process of peer review and evaluation indicating effectiveness in 
improving health outcomes, generally demonstrated through systematic reviews. 
Best practices framework: A conceptual framework that includes important aspects of impact and quality to provide 
a common lexicon and criteria for assessing and strengthening public health practice.
Clinical decision support system (CDSS): A program that analyzes data entered into an electronic health record to 
trigger reminders, flags, and treatment protocols to help health care providers make clinical decisions.
Collaborative drug therapy management (CDTM): Qualified pharmacists are permitted to assume professional 
responsibility for performing a full scope of services (e.g., ordering drug-therapy laboratory tests; administrating 
drugs; and selecting, initiating, monitoring, continuing, and adjusting drug regimens). Authority of CDTM is defined in 
the state’s pharmacy practice within the scope of practice section.
Collaborative practice agreements (CPAs): A strategy to expand the pharmacist’s role in team-based care with other 
providers and improving health outcomes. The range of services authorized under each state’s practice act varies. 
Community Guide (The Guide to Community Preventive Services): A resource with a collection of evidence-based 
findings from the Community Preventive Services Task Force (Task Force). This resource was created to help states, 
communities, community organizations, business, health care organizations, and schools select interventions to 
improve health and prevent disease. 
Community health worker (CHW): The American Public Health Association defines a CHW as a “frontline public 
health worker who is a trusted member of and/or has an unusually close understanding of the community being 
served. This trusting relationship enables the CHW to serve as a liaison/link/intermediary between health/social 
services and the community to facilitate access to services and improve the quality and cultural competence of service 
delivery. In addition, a CHW builds individual and community capacity to improve health outcomes by increasing 
health knowledge and self-sufficiency through a range of activities such as outreach, community education, informal 
counseling, the provision of social support and advocacy.”
Community Preventive Services Task Force (Task Force): An independent, nonfederal, unpaid panel of public 
health and prevention experts that provides evidence-based findings and recommendations about community 
preventive services, programs, and policies to improve health. Findings are summarized within the Guide to 
Community Preventive Services. The Task Force issues findings based on systematic reviews of effectiveness and 
economic evidence that are conducted with a methodology developed by the Community Guide Branch, which is 
based at CDC.
Community programs linked to clinical services: A term to describe connecting community programs with health 
care systems to improve disease prevention, care, and management. 
Continuum of Evidence of Effectiveness: A tool to describe and assess various components in determining the 
strength of the best available research evidence on a program, practice, or policy’s effectiveness. It illuminates the 
strengths and weaknesses of the research evidence and offers guidance on next steps for consideration. It consists of 
six dimensions, each of which addresses a specific aspect of the best available research evidence (e.g., effect, internal 
validity, research design, independent replication, implementation guidance, and external and ecological validity).
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Effect: One of the six dimensions of CDC’s Continuum of Evidence of Effectiveness. Effectiveness is important because 
it tells us whether a prevention strategy is having an impact on the outcomes of interest. The most effective strategies 
produce preventive effects in the short term, long term, or both. The effectiveness of a strategy is based on its intent 
and design. 
E-Prescribing: A prescriber’s ability to electronically send an accurate, error-free and understandable prescription 
directly to a pharmacy from the point-of-care. This is an important element in improving the quality of patient care.
External ecological validity: One of the six dimensions of CDC’s Continuum of Evidence of Effectiveness. External 
validity refers to whether a program, practice, or policy can demonstrate preventive effects among a wide range of 
populations and contexts. Ecological validity refers to whether the program components and procedures approximate 
the “real-life” conditions specific to a specific setting. 
Health care system interventions: Effective delivery and use of quality care and preventive services in clinical settings. 
Implementation guidance: One of the six dimensions of CDC’s Continuum of Evidence of Effectiveness. This includes 
any and all services and/or materials that aid in the implementation of a prevention strategy in a different setting, 
including but not limited to “training, coaching, technical assistance, support materials, organizational/systems 
change consultation, and manuals/guides.”
Independent replication: One of the six dimensions of CDC’s Continuum of Evidence of Effectiveness. This helps 
determine whether or not a prevention program can be replicated and implemented with other participants, and 
produce the same effects. Independent replications are not used to determine whether a program can be successfully 
generalized to a broad variety of settings or populations.
Internal validity: One of the six dimensions of CDC’s Continuum of Evidence of Effectiveness. This refers to the extent 
to which the short-term and/or long-term outcomes of a program, practice, or policy can truly be attributed to it or if 
these outcomes could have been caused by something else. 
Medication therapy management (MTM): According to the American Pharmacists Association (APhA), “MTM 
is a service or group of services that optimize therapeutic outcomes for individual patients. Medication therapy 
management services include medication therapy reviews, pharmacotherapy consults, anticoagulation management, 
immunizations, health and wellness programs and many other clinical services. Pharmacists provide medication 
therapy management to help patients get the best benefits from their medications by actively managing drug therapy 
and by identifying, preventing and resolving medication-related problems.” 
Public health domains of chronic disease prevention: Four key domains of CDC’s National Center for Chronic 
Disease Prevention and Health Promotion, which include (1) epidemiology and surveillance, (2) environmental 
approaches, (3) health care system interventions, and (4) community programs linked to clinical services. 
Rapid Synthesis and Translation Process (RSTP) Framework: A six-step process developed by and for CDC’s 
Division of Violence Prevention in collaboration with partners in order to expedite the transfer of research knowledge 
to practitioners, specifically to prevent violence. The six-steps include the following: (1) topics suggested by end 
user(s); (2) scan findings; (3) sort for relevance; (4) synthesize results; (5) translate for end user(s); and (6) end user 
expert review. 
Self-measured blood pressure monitoring (SMBP): The regular measurement of blood pressure by the patient 
outside the clinical setting, either at home or elsewhere. It is sometimes known as “home blood pressure monitoring.”
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Team-based care: Team-based health care is the provision of health services to individuals, families, and/or their 
communities by at least two health providers who work collaboratively with patients and their caregivers—to the 
extent preferred by each patient—to accomplish shared goals within and across settings to achieve coordinated, 
high-quality care. 
Type of evidence or research design: One of the six dimensions of CDC’s Continuum of Evidence of Effectiveness. 
The nature of the design of the research study determines whether and how to answer the research questions related 
to effectiveness. The more rigorous the research design, the higher its internal validity and the more likely outcomes 
can be attributed to the program, practice, or policy.
For more information, please contact Centers for Disease Control and Prevention
1600 Clifton Road NE, Atlanta, GA 30333
Telephone: 1-800-CDC-INFO (232-4636)/TTY: 1-888-232-6348
Email: cdcinfo@cdc.gov 
Website: www.cdc.gov
